ClinicalTrials.gg
Not yet recruitingNCT05656209Updated Dec 19, 2022

LA Improves the Prognosis of Patients With ICVD After Surgery

An interventional study of Lactobacillus acidophilus in Ischemia; Cerebrovascular and Cognitive Impairment, sponsored by Huaqiu Zhang. Not yet recruiting. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-12-19.

Sponsored by Huaqiu Zhang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
All
01

Study summary

Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis".

Read the detailed description

Ischemic cerebrovascular disease, as a common form of stroke, is one of the main causes of global morbidity and mortality. The mortality rate of this disease is relatively high, and the treatment prognosis is poor, which will cause serious harm to the life and safety of patients. The optimal treatment for ischemic cerebrovascular disease is still unclear, and the effects of different treatments are still controversial. Therefore, it is of great clinical significance to explore a safe and simple adjuvant treatment method to help patients recover their nervous system function faster and better.

At present, numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. Adding intestinal probiotics can improve the intestinal flora distribution, and significantly improve cognitive function in elderly patients with mild cognitive impairment and prevention of brain atrophy. Lactobacillus acidophilus is rich in short chain fatty acids (SCFA). Clinical studies have shown that SCFA levels are negatively correlated with the severity and prognosis of ischemic stroke. Numerous studies have demonstrated that the intestinal supply short chain fatty acids can improve cognitive function, in the middle cerebral artery occlusion (MCAO) induced by acute cerebral ischemia model, rich in the intestines of SCFA can cure acute cerebral ischemia in mice induced by nerve injury. More importantly, in mice with acute cerebral ischemia induced by middle cerebral artery occlusion (MCAO) and chronic cerebral ischemia caused by bilateral common carotid artery stenosis (BCAS), we have previously found that mice have cognitive impairment, accompanied by intestinal flora dysregulation.

Lactobacillus acidophilus administration has a significant effect on improving cognitive function. Based on the above research background and the basis of previous studies, the researchers believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis", and increase the reliability and scope of revascularization, and ultimately improve the prognosis of patients with ischemic cerebrovascular disease.

02

Conditions studied

  • Ischemia; Cerebrovascular
  • Cognitive Impairment
03

In context

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

This study's planned enrollment of 236 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.

Browse Cerebral Infarction studies →

Lead sponsor

Huaqiu Zhang is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 35-60 years old;
  2. Diagnosed as ischemic cerebrovascular disease, mild to moderate symptoms, can independently complete the neuropsychological test;
  3. No previous operation history;
  4. The modified Rankin scale score was 0 or 1;
  5. Carotid artery ischemic symptoms ≤3 months before treatment;
  6. Surgical treatment;

Exclusion criteria

Exclusion Criteria:

  1. Previous dementia;
  2. hearing or visual impairment;
  3. drugs that may or are known to affect cognitive abuse;
  4. alcohol addiction;
  5. Diagnosis of depression, schizophrenia and other mental diseases;
  6. MRI showed severe cerebral infarction;
  7. Patients with Lactobacillus acidophilus allergy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • No intervention
    Control group

    The patient received conventional care after surgery, with no other interventions.

  • Experimental
    LA treatment group

    The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.

    Dietary Supplement: Lactobacillus acidophilus

Interventions

  • Dietary supplementLacteolStudies of LacteolLacteol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.

06

What researchers measure

Primary outcomes

  1. Mini-mental State Examination (MMSE, 0-30) scale

    Higher scale scores mean better cognitive function.

    Time frame: Three months.

  2. Montreal Cognitive Assessment (MoCA, 0-30) scale

    Higher scale scores mean better cognitive function.

    Time frame: Three months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Dec 2022, 0 months later.

Of 27 interventional studies with no phase under Cerebral Infarction, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Dec 19, 2022
StartEst.
Dec 18, 2022
Primary completionEst.
Dec 18, 2022
CompletionEst.
Dec 31, 2027
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05656209
Lead sponsor
Huaqiu Zhang
Responsible party
Huaqiu Zhang (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Dec 19, 2022
Start date
Dec 18, 2022 (estimated)
Primary completion
Dec 18, 2022 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 19, 2022

Study contacts

Huaqiu Zhang, PhD
Contact
zhanghq@tjh.tjmu.edu.cn
13808631221
Huaqiu Zhang, PhD
study director · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacteol

Start the discussion